Physician profile
Patrick E Weldon
NPI 1003907460
$84,524.56
in general payments reported to CMS, 2019-2025
34 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $8,208 · 2021: $8,757 · 2022: $15K · 2023: $15K · 2024: $23K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $4,964 · Consulting Fee: $2,455 · Travel and Lodging: $776 · Education: $93.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,172.13 |
| Food and Beverage | $4,963.96 |
| Consulting Fee | $2,455.00 |
| Travel and Lodging | $775.91 |
| Education | $93.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $75,309.77 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Corium, LLC | $1,900.95 | 2022-2023 | Adlarity |
| Sk Life Science, INC. | $1,131.54 | 2020-2025 | |
| Amgen INC. | $643.41 | 2019-2022 | |
| Lilly USA, LLC | $613.82 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Abbvie INC. | $575.42 | 2021-2025 | |
| Genzyme Corporation | $505.20 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $398.22 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $382.45 | 2024-2025 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $363.79 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $343.28 | 2023-2024 | Aptiom |
| Argenx US, INC. | $317.04 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $246.30 | 2020-2025 | Nayzilam, Briviact |
| Eisai INC. | $238.00 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $232.90 | 2019-2025 | Ingrezza, Ongentys |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $214.95 | 2022-2025 | Vyepti |
| Biogen, INC. | $206.82 | 2020-2025 | Vumerity |
| Pfizer INC. | $196.23 | 2019-2025 | |
| Emd Serono, INC. | $158.99 | 2019-2024 | Mavenclad |
| Medtronic, INC. | $118.61 | 2022-2023 | Reveal Linq |
| Impel Pharmaceuticals INC. | $74.41 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $57.62 | 2023-2025 | Nuedexta, Rexulti |
| Supernus Pharmaceuticals, INC. | $50.00 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.79 | 2022 | |
| Livanova USA, INC. | $27.21 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Boston Scientific Corporation | $26.53 | 2025 | Wavewriter Alpha Prime 16 |
| Assertio Therapeutics, INC. | $26.06 | 2020 | |
| Ge Healthcare | $22.69 | 2019 | |
| Allergan, INC. | $22.03 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.05 | 2020 | |
| Janssen Pharmaceuticals, INC | $18.91 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Acadia Pharmaceuticals INC | $15.11 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Weldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.